TheraRadar
← Back
Data updated: Mar 29, 2026

INVAGEN PHARMS

CardiovascularNeurologyImmunology
Generics

INVAGEN PHARMS is a generic drug manufacturer focused on Cardiovascular, Neurology, Immunology. Key products include LEUPROLIDE ACETATE FOR DEPOT SUSPENSION.

2005
Since
55
Drugs
-
Trials
829
Approved (2yr)

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Cardiovascular 32%
6 drugs
Neurology 26%
5 drugs
Immunology 16%
3 drugs
Oncology 16%
3 drugs
Metabolic 11%
2 drugs

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...